Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions

International Journal of Pharmaceutics

Volumn 396, Issue 1-2, 2010, Pages 1-10

  Damian, Festo ^a   Fabian, Judit ^a   Friend, David R ^b   Kiser, Patrick F ^a,c  

^a Department of Electrical and Computer Engineering   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Complexation; Microbicides; Solubility; Stability; Sulfobutylether cyclodextrin; UC781

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CITRIC ACID; EDETIC ACID; GLUTATHIONE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; SODIUM METABISULFITE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; ANILIDE; ANTIOXIDANT; ANTIVIRUS AGENT; BETA CYCLODEXTRIN DERIVATIVE; DIMETHYL SULFOXIDE; EXCIPIENT; FUMARIC ACID; FUMARIC ACID DERIVATIVE; FURAN DERIVATIVE; MACROGOL DERIVATIVE; POLYSORBATE; SBE4-BETA-CYCLODEXTRIN; SULFITE;

AQUEOUS SOLUTION; ARTICLE; DRUG DEGRADATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CHEMICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; DRUG FORMULATION; HEAT; MEDICINAL CHEMISTRY; OXIDATION REDUCTION REACTION; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TIME;

ANILIDES; ANTIOXIDANTS; ANTIVIRAL AGENTS; ASCORBIC ACID; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; DIMETHYL SULFOXIDE; DRUG COMPOUNDING; DRUG STABILITY; EDETIC ACID; EXCIPIENTS; FUMARATES; FURANS; GLUTATHIONE; HOT TEMPERATURE; MODELS, CHEMICAL; OXIDATION-REDUCTION; POLYETHYLENE GLYCOLS; POLYSORBATES; SOLUBILITY; SULFITES; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; VITAMIN E;

EID: 77955050125     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.024     Document Type: Article

References (57)

1. Agharkar S., Lindenbaum S., Higuchi T. Enhancement of solubility of drug salts by hydrophilic counterions: properties of organic salts of an antimalarial drug. J. Pharm. Sci. 1976, 65:747-749.
2. Ahn H.J., Kim K.M., Choi S.J., Kim C.K. Effects of cyclodextrin derivatives on bioavailability of ketoprofen. Drug Dev. Ind. Pharm. 1997, 23:397-401.
3. Al Omari M.M., Zoubi R.M., Hasan E.I., Khader T.Z., Badwan A.A. Effect of light and heat on the stability of montelukast in solution and in its solid state. J. Pharmacol. Biomed. Anal. 2007, 45:465-471.
4. Allen L.V. The Art and Science of Pharmaceutical Compounding 2008, American Pharmacists Association, Washington, DC. 3rd ed.
5. Balzarini J., Brouwer W.G., Dao D.C., Osika E.M., De Clercq E. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodefficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 1996, 40:1454-1466.
6. Balzarini J., Naesens L., Verbeken E., Laga M., Van Damme L., Parniak M., Van Mellaert L., Anné J., De Clercq E. Preclinical studies on the thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998, 12:1129-1138.
7. Barnard J., Borkow G., Parniak M.A. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 1997, 36:7786-7792.
8. Borkow B., Arion D., Wainberg M.A., Parniak M.A. The thiocarboxanilide non-nucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1999, 43:259-263.
9. Brewster M.E., Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 2007, 59:645-666.
10. Brewster M.E., Loftsson T., Estes K.S., Lin J.L., Fri{eth}riksdóttir H. Effects of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride. Int. J. Pharm. 1992, 79:289-299.
11. Buchanan C.M., Buchanan N.L., Edgar K.J., Little J.L., Malcolm M.O., Ruble K.M., Wacher V.J., Wempe M.F. Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-β-cyclodextrin formulations. J. Pharm. Sci. 2007, 96:644-660.
12. Chiou W., Riegelman S. Pharmaceutical application of solid dispersions. J. Pharm. Sci. 1971, 60:1281-1302.
13. Clinicaltrials.Gov., 2009. Study of UC781 vaginal microbicide. Available at http://clinicaltrials.gov/ct2/show/NCT00132444.
14. Damian F., Blaton N., Desseyn H., Clou K., Naesens L., Balzarini J., Kinget R., Augustijns P., Van Den Mooter G. Solid state properties of pure UC-781 and solid dispersions with polyvinylpyrrolidone (PVP K30). J. Pharm. Pharmacol. 2001, 53:1109-1116.
15. D'cruz O.J., Uckun F.M. Clinical development of microbicides for the prevention of HIV infection. Curr. Pharm. Des. 2004, 10:315-336.
16. D'cruz O.J., Uckun F.M. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J. Antimicrob. Chemother. 2006, 57:411-423.
17. Enever R.P., Li L.W., Shotton E. Factors influencing decomposition rate of amitriptyline hydrochloride in aqueous solution. J. Pharm. Sci. 1977, 66:1087-1089.
18. Evans R.K., Nawrocki D.K., Isopi L.A., Williams D.M., Casimiro D.R., Chin S., Chen M., Zhu D.M., Shiver J.W., Volkin D.B. Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci. 2004, 93:2458-2475.
19. Fletcher P., Kiselyeva Y., Wallace G., Romano J., Griffin G., Margolis L., Shattock R. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J. Virol. 2005, 79:11179-11186.
20. Glynn J.R., Carael M., Buve A., Kahindo M., Chege J., Musonda R., Kaona F., Buve A. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. AIDS 2001, 15(Suppl. 4):S51-S60.
21. Goddeeris C., Willems T., Van Den Mooter G. Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC781. Eur. J. Pharm. Sci. 2008, 34:293-302.
22. Gupta K.M., Poursaid A.E., Pearce S.M., Aliyar H.A., Tresco P.A., Mitchnick M.A., Kiser P.F. Polyurethane intravaginal ring for controlled delivery of dapivirine, a non-nucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci. 2008, 97:4228-4239.
23. Higuchi T., Connors K.A. Phase-solubility techniques. Advances in Analytical Chemistry and Instrumentation, 4 1965, Interscience, New York, pp. 117-122.
24. Hong J., Lee E., Carter J.C., Masse J.A., Oksanen D.A. Antioxidant-accelerated oxidative degradation: a case study of transition metal ion catalyzed oxidation in formulation. Pharm. Dev. Technol. 2004, 9:171-179.
25. Hovorka S., Schöneich C. Oxidative degradation of pharmaceuticals: theory, mechanisms and inhibition. J. Pharm. Sci. 2001, 90:253-269.
26. Ikeda H., Chiba K., Kanou A., Hirayama N. Prediction of solubility of drugs by conductor-like screening model for real solvents. Chem. Pharm. Bull. 2005, 53:253-255.
27. Kasraian K., Kuzniar A.A., Wilson G.G., Wood J.A. Developing an injectable formula containing an oxygen-sensitive drug: a case study of danofloxacin injectable. Pharm. Dev. Technol. 1999, 4:475-480.
28. Kramarenko G.G., Hummel S.G., Martin S.M., Buettner G.R. Ascorbate reacts with singlet oxygen to produce hydrogen peroxide. Photochem. Photobiol. 2006, 82:1634-1637.
29. Krishnan S., Dunbar M.S., Minnis A.M., Medlin C.A., Gerdts C.E., Padian N.S. Poverty, gender inequities, and women's risk of human immunodeficiency virus/AIDS. Ann. N.Y. Acad. Sci. 2008, 1136:101-110.
30. Lemesle-Lamachea V., Wouessidjewea D., Chéronb M., Duchêne D. Study of β-cyclodextrin and ethylated β-cyclodextrin salbutamol complexes, in vitro evaluation of sustained-release behaviour of salbutamol. Int. J. Pharm. 1996, 141:117-124.
31. ® (sulfobutyl ether-β-cyclodextrin). J. Pharm. Sci. 2003, 92:922-926.
32. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
33. Loftsson T., Frioriksdottir H., Siguroardottir A.M., Ueda H. The effect of water-soluble polymers on drug-cyclodextrin complexation. Int. J. Pharm. 1994, 110:169-177.
34. Loftsson T., Magnúsdóttir A., Másson M., Sigurjónsdóttir J.F. Self-association and cyclodextrin solubilization of drugs. J. Pharm. Sci. 2002, 91:2307-2316.
35. Loftsson T., Hreinsdóttir D., Másson M. Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 2005, 302:18-28.
36. Loftsson T., Hreinsdóttir D., Másson M. The complexation efficiency. J. Inc. Phenom. Macrocycl. Chem. 2007, 57:545-552.
37. Ma D.Q., Rajewski R.A., Velde D.V., Stella V.J. Comparative effects of (SBE) 7m-β-CD and HP-β-CD on the stability of two anti-neoplastic agents, melphalan and carmustine. J. Pharm. Sci. 2000, 89:275-287.
38. Maia A.M., Baby A.R., Pinto C.A.S.O., Yasaka W.J., Suenaga E., Kaneko T.M., Valeria R.V.M. Influence of sodium metabisulfite and glutathione on the stability of vitamin C in O/W emulsion and extemporaneous aqueous gel. Int. J. Pharm. 2006, 322:130-135.
39. Microbicide pipeline, 2009. HIV/STI prevention research and development: pipeline update of microbicide and PrEP candidates. http://www.microbicide.org/cs/pipeline.
40. Patton D.L., Sweeney Y.T., Balkus J.E., Rohan L.C., Moncla B.J., Parniak M.A., Hillier S.L. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob. Agents Chemother. 2007, 51:1608-1615.
41. Pelemans H., Esnouf R., De Clercq E., Balzarini J. Mutational analysis of Trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT). Mol. Pharmacol. 2000, 57:954-960.
42. Sassi A.B., Isaacs C.E., Moncla B.J., Gupta P., Sharon S.L., Rohan L.C. Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J. Pharm. Sci. 2007, 97:3123-3139.
43. Schwartz J.L., Kovalevsky G., Lai J.J., Ballagh S.A., Mccormick T., Douville K., Mauck C.K., Callahan M. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 2008, 35:414-419.
44. Serajuddin A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
45. Shah K.A., Das Gupta V., Stewart K.R. Effect of pH, chlorobutanol, cysteine hydrochloride, ethylenediaminetetraacetic acid, propylene glycol, sodium metabisulfite, and sodium sulfite on furosemide stability in aqueous solutions. J. Pharm. Sci. 1980, 69:594-596.
46. Sortino S., Giuffrida S., De Geuidi G., Chillemi R., Petralia S., Marconi G., Condorelli G., Sciuto S. The photochemistry of flutamide and its inclusion complex with β-cyclodextrin: dramatic effect of the microenvironment on the nature and on the efficiency of the photodegradation pathways. Photochem. Photobiol. 2001, 73:6-13.
47. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug Discov. 2002, 1:977-985.
48. Trapani A., Laquintana V., Lopedota A., Franco M., Latrofa A., Talani G., Sanna E., Trapani G., Liso G. Evaluation of new propofol aqueous solutions for intravenous anesthesia. Int. J. Pharm. 2004, 278:91-98.
49. UNAIDS, 2008. Joint United Nations Progamme on HIV/AIDS: Report on the global AIDS epidemic.
50. Underberg W.J.M. Oxidative degradation of pharmaceutically important phenothiazines III: kinetics and mechanism of promethazine oxidation. J. Pharm. Sci. 1978, 67:1133-1138.
51. Varsha P.A.K., Vinod V., Sheetal D.L.M. Ternary complexation of carvedilol, β-cyclodextrin and citric acid for mouth-dissolving tablet formulation. Acta Pharm. 2009, 59:121-132.
52. Vermeire A., Remon J.P. Stability and compatibility of morphine. Int. J. Pharm. 1999, 187:17-51.
53. Won C.M., Tang S.H., Strohbeck C.L. Photolytic and oxidative degradation of an antiemetic agent, RG 12915. Int. J. Pharm. 1995, 121:95-105.
54. Woolfson A.D., Malcolm R.K., Morrow R.J., Toner C.F., Mccullagh S.D. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int. J. Pharm. 2006, 325:82-89.
55. Yang, G., 2008. UC781:β-cyclodextrin complexation and formulation as an anti-HIV microbicide. Ph.D. Thesis, University of Pittsburgh, Pittsburgh, USA.
56. Yang G., Jain N., Yalkowsky S.H. Combined effect of SLS and (SBE)7M-β-CD on the solubilization of NSC-639829. Int. J. Pharm. 2004, 269:141-148.
57. Yang H., Parniak M.A., Isaacs C.E., Hillier S.L., Rohan L.C. Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781. AAPS J. 2008, 10:606-613.